

Quanterix

Quanterix Named Edison Award Finalist

Quanterix' Simoa HD-1 Analyzer recognized as a leading diagnostics innovation for its single molecule detection ability

Lexington, Mass. – February 13, 2015 — [Quanterix Corporation](#), a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that their [Simoa HD-1 Analyzer](#) has been named a 2015 award finalist by the internationally renowned Edison Awards™, alongside past diagnostic winners, such as Thermo Scientific and GE Healthcare. The distinguished awards, inspired by Thomas Edison's persistence and inventiveness, recognize innovation, creativity and ingenuity in the global economy.

"We are honored to be recognized for this prestigious award and thrilled that our company has been named a finalist alongside some of the oldest, most impactful innovators in the industry," said Kevin Hrusovsky, Executive Chairman, Quanterix. "This acknowledgment validates the exciting work Quanterix is doing with our ground breaking ultrasensitive Simoa technology, and provides us with the opportunity to further spread awareness on our single molecule array technology and how it truly has the ability to unlock a world of insight into disease detection, diagnosis and patient treatment."

Edison Award nominees are judged by more than 3,000 senior business executives and academics from across the nation whose votes acknowledge the finalists' success in meeting the award's stringent criteria of quality. Award winners will be announced April 23, 2015 at the Edison Awards Annual Gala, held in the historic Ballroom of The Capitale in New York City.

About Edison Awards

The Edison Awards is a program conducted by Edison Universe, a 501(c)(3) charitable organization dedicated to fostering future innovators. For more information about the Edison Awards, Edison Universe and a list of past winners, visit www.edisonawards.com.

About Quanterix

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.Quanterix.com.

###

Contacts:

Nikki Festa & Caitlyn Keating
PAN Communications
617-502-4300
quanterix@pancomm.com